Table I.
Clinical feature according to the biomarkers.
| LMP1 | miR-155∆ | ||||
|---|---|---|---|---|---|
| Clinical feature | All patients n=82 (%) | Positive (n=41) | Negative (n=41) | High (n=42) | Very-high (n=40) |
| Age at diagnosis, n (%) | |||||
| ≤60 | 27 (33) | 12 (29) | 15 (37) | 17 (40) | 10 (25) |
| >60 | 55 (67) | 29 (71) | 26 (63) | 25 (60) | 30 (75) |
| Sex, n (%) | |||||
| Male | 48 (58) | 24 (59) | 24 (59) | 26 (62) | 22 (55) |
| Female | 34 (42) | 17 (41) | 17 (41) | 16 (38) | 18 (45) |
| Serum LDH level, n (%) | |||||
| ≤200 U/l | 52 (63) | 27 (65) | 25 (61) | 26 (62) | 26 (65) |
| >200 U/l | 30 (37) | 14 (35) | 16 (39) | 16 (38) | 14 (35) |
| B symptoms, n (%) | |||||
| Absent | 49 (59) | 24 (59) | 25 (61) | 24 (57) | 25 (63) |
| Present | 33 (41) | 17 (41) | 16 (39) | 18 (43) | 15 (37) |
| Stage, n (%) | |||||
| I | 17 (21) | 6 (15) | 11 (27) | 9 (21) | 8 (20) |
| II | 14 (17) | 7 (17) | 7 (17) | 7 (17) | 7 (17) |
| III | 19 (23) | 11 (27) | 8 (19) | 16 (38) | 3 (8) |
| IV | 32 (39) | 17 (41) | 15 (37) | 10 (24) | 22 (55) |
| IPI, n (%) | |||||
| 0 | 5 (6) | 0 (0) | 5 (12) | 3 (7) | 2 (5) |
| 1 | 18 (22) | 10 (24) | 8 (19) | 11 (26) | 7 (17) |
| 2 | 35 (43) | 21 (51) | 14 (35) | 18 (43) | 17 (43) |
| 3 | 14 (17) | 6 (15) | 8 (19) | 6 (14) | 8 (20) |
| 4 | 10 (12) | 4 (10) | 6 (15) | 4 (10) | 6 (15) |
| ENE, n (%) | |||||
| Yes | 45 (55) | 23 (56) | 22 (54) | 18 (43) | 27 (68) |
| No | 37 (45) | 18 (44) | 19 (46) | 24 (57) | 13 (32) |
| Rituximab, n (%) | |||||
| Yes | 23 (28) | 8 (19) | 15 (37) | 17 (40) | 6 (15) |
| No | 59 (72) | 33 (81) | 26 (63) | 25 (60) | 34 (85) |
miR-155∆, miR-155 expressed highly in all the lymphoma samples included in this study compared with lymphadenitis. The lymphoma samples were separated into two groups: High (≤12 folds) and very-high (>12 folds). miR, microRNA; LMP1, latent membrane protein 1; LDH, lactate dehydrogenase; IPI, international prognostic factors index; ENE, extranodal extension.